Published in Trends Neurosci on February 01, 2012
Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS (2012) 1.32
Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol (2013) 1.08
Distinct patterns of cerebral extravasation by Evans blue and sodium fluorescein in rats. PLoS One (2013) 1.00
Brain region mapping using global metabolomics. Chem Biol (2014) 0.92
Combinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infection. J Neuroimmune Pharmacol (2013) 0.90
GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration. Antimicrob Agents Chemother (2013) 0.86
Targeting HIV transcription: the quest for a functional cure. Curr Top Microbiol Immunol (2015) 0.85
HIV-1 transgenic female rat: synaptodendritic alterations of medium spiny neurons in the nucleus accumbens. J Neuroimmune Pharmacol (2014) 0.84
Nano-NRTIs demonstrate low neurotoxicity and high antiviral activity against HIV infection in the brain. Nanomedicine (2013) 0.83
Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice. Mol Neurodegener (2014) 0.82
Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice. Mol Neurobiol (2015) 0.80
HIV-1 proteins, Tat and gp120, target the developing dopamine system. Curr HIV Res (2015) 0.80
Humanized mouse models for HIV-1 infection of the CNS. J Neurovirol (2014) 0.79
Commentary: Animal models of neuroAIDS. J Neuroimmune Pharmacol (2012) 0.79
Effects of HIV and Methamphetamine on Brain and Behavior: Evidence from Human Studies and Animal Models. J Neuroimmune Pharmacol (2016) 0.78
Insights into end-organ injury in HIV infection: dynamics of monocyte trafficking to the brain in SIV encephalitis. Am J Pathol (2015) 0.76
Generation and Disease Model Relevance of a Manganese Enhanced Magnetic Resonance Imaging-Based NOD/scid-IL-2Rγ c (null) Mouse Brain Atlas. J Neuroimmune Pharmacol (2015) 0.75
Influence of age, irradiation and humanization on NSG mouse phenotypes. Biol Open (2015) 0.75
Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery. J Neuroimmune Pharmacol (2017) 0.75
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood (2002) 7.78
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science (1987) 6.56
Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood (2005) 6.16
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32
Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature (1994) 3.87
Human immunodeficiency virus type 1, human protein interaction database at NCBI. Nucleic Acids Res (2008) 3.54
T cell antigen receptor signal transduction: a tale of tails and cytoplasmic protein-tyrosine kinases. Cell (1993) 3.25
Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell (1998) 3.22
Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev (2009) 2.86
An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A (2001) 2.28
A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis (2005) 2.25
Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. J Virol (2006) 2.24
Characterization and molecular cloning of a bovine lentivirus related to human immunodeficiency virus. Nature (1987) 2.23
Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin Immunol (2010) 2.19
Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS (2000) 1.93
The immunopathogenesis of HIV infection. Adv Immunol (1989) 1.91
Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol (2009) 1.85
Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses (2008) 1.84
Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS. J Clin Invest (2005) 1.78
HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci (2007) 1.64
Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol (2003) 1.62
Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci (2002) 1.58
Human immunodeficiency virus encephalitis in SCID mice. Am J Pathol (1996) 1.55
Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood (2005) 1.54
Renaissance for mouse models of human hematopoiesis and immunobiology. Nat Immunol (2009) 1.54
Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice. Hum Immunol (2009) 1.53
A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron (2009) 1.48
Disturbed CD4+ T cell homeostasis and in vitro HIV-1 susceptibility in transgenic mice expressing T cell line-tropic HIV-1 receptors. J Exp Med (1998) 1.46
Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol (2010) 1.42
The utilization of humanized mouse models for the study of human retroviral infections. Retrovirology (2009) 1.42
HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1beta. Glia (2006) 1.40
Persistent expression of Ia antigen and viral genome in visna-maedi virus-induced inflammatory cells. Possible role of lentivirus-induced interferon. J Exp Med (1985) 1.39
MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6 regulates astrocyte survival. FASEB J (2010) 1.39
Interferon-independent, human immunodeficiency virus type 1 gp120-mediated induction of CXCL10/IP-10 gene expression by astrocytes in vivo and in vitro. J Virol (2001) 1.35
A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. Proc Natl Acad Sci U S A (2005) 1.32
Animal transgenesis: an overview. Brain Struct Funct (2009) 1.29
Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci (2003) 1.28
Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release (2010) 1.28
CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol (2010) 1.27
A model of human immunodeficiency virus encephalitis in scid mice. Proc Natl Acad Sci U S A (1993) 1.25
Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol (2002) 1.23
Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J Exp Med (2002) 1.23
Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J Neurosci (2011) 1.22
Primate models of AIDS. Microbes Infect (2000) 1.21
Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One (2010) 1.20
Interferon-alpha causes neuronal dysfunction in encephalitis. J Neurosci (2009) 1.18
Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci (2005) 1.16
Molecular and cellular mechanisms of neuronal cell death in HIV dementia. Neurotox Res (2005) 1.15
Alcohol abuse enhances neuroinflammation and impairs immune responses in an animal model of human immunodeficiency virus-1 encephalitis. Am J Pathol (2006) 1.15
Neuromodulatory activities of CD4+CD25+ regulatory T cells in a murine model of HIV-1-associated neurodegeneration. J Immunol (2009) 1.14
Macrophage-induced inflammation affects hippocampal plasticity and neuronal development in a murine model of HIV-1 encephalitis. Glia (2005) 1.12
Rodent models for HIV-1 infection and disease. Curr HIV Res (2003) 1.12
HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches. Curr Opin Neurol (2009) 1.12
Selective infection of CD4+ effector memory T lymphocytes leads to preferential depletion of memory T lymphocytes in R5 HIV-1-infected humanized NOD/SCID/IL-2Rgammanull mice. Virology (2009) 1.11
Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS. J Neuroimmune Pharmacol (2010) 1.10
HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription. Proc Natl Acad Sci U S A (2007) 1.09
Further characterization of the spatial learning deficit in the human immunodeficiency virus-1 transgenic rat. J Neurovirol (2008) 1.09
Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis. Am J Pathol (2010) 1.09
Impaired spatial cognition and synaptic potentiation in a murine model of human immunodeficiency virus type 1 encephalitis. J Neurosci (2002) 1.08
Growth failure and AIDS-like cachexia syndrome in HIV-1 transgenic mice. Virology (1994) 1.08
Controversies in the pathogenesis of HIV-associated renal diseases. Nat Rev Nephrol (2009) 1.08
Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis. J Immunol (2007) 1.07
Retracted Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in brain of HIV-1 transgenic rats. J Neuroinflammation (2011) 1.06
Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of Interferon-alpha in the brain. AIDS (2007) 1.06
Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. Brain Res (1996) 1.05
HIV-1 infected mononuclear phagocyte secretory products affect neuronal physiology leading to cellular demise: relevance for HIV-1-associated dementia. J Neurovirol (2000) 1.04
Neuroregulatory events follow adaptive immune-mediated elimination of HIV-1-infected macrophages: studies in a murine model of viral encephalitis. J Immunol (2004) 1.03
HIV-1 Tat and morphine have interactive effects on oligodendrocyte survival and morphology. Glia (2009) 1.02
Enhancement of human immunodeficiency virus (HIV)-specific CD8+ T cells in cerebrospinal fluid compared to those in blood among antiretroviral therapy-naive HIV-positive subjects. J Virol (2008) 1.02
Rabbit cells expressing human CD4 and human CCR5 are highly permissive for human immunodeficiency virus type 1 infection. J Virol (1998) 1.02
Relief of preintegration inhibition and characterization of additional blocks for HIV replication in primary mouse T cells. PLoS One (2008) 1.01
Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic mice. AIDS (1999) 1.01
An immune control model for viral replication in the CNS during presymptomatic HIV infection. Brain (2005) 1.01
SCID mice with HIV encephalitis develop behavioral abnormalities. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.00
Neuroprotective activities of CEP-1347 in models of neuroAIDS. J Immunol (2009) 0.98
Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J Cereb Blood Flow Metab (2006) 0.97
The development of animal model systems for HIV-1 encephalitis and its associated dementia. J Neurovirol (1995) 0.97
Neuropathologic and neuroinflammatory activities of HIV-1-infected human astrocytes in murine brain. Glia (2006) 0.97
Testing antiretroviral drug efficacy in conventional mice infected with chimeric HIV-1. AIDS (2007) 0.96
Mouse T-cells restrict replication of human immunodeficiency virus at the level of integration. Retrovirology (2008) 0.95
Visna virus infection of American lambs. Science (1974) 0.94
Reduction in glial immunity and neuropathology by a PAF antagonist and an MMP and TNFalpha inhibitor in SCID mice with HIV-1 encephalitis. J Neuroimmunol (2001) 0.94
Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis. Sci China Life Sci (2010) 0.94
Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders. J Neuroimmunol (2009) 0.93
Mice transgenic for monocyte-tropic HIV type 1 produce infectious virus and display plasma viremia: a new in vivo system for studying the postintegration phase of HIV replication. AIDS Res Hum Retroviruses (2000) 0.93
Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score. Neurology (2011) 0.93
Levels of human immunodeficiency virus type 1 (HIV-1) replication in macrophages determines the severity of murine HIV-1 encephalitis. J Neurovirol (2004) 0.92
Protection against human immunodeficiency virus type 1 Tat neurotoxicity by Ginkgo biloba extract EGb 761 involving glial fibrillary acidic protein. Am J Pathol (2007) 0.92
Peroxisome proliferator-activated receptor-gamma activation suppresses HIV-1 replication in an animal model of encephalitis. AIDS (2008) 0.90
Hippocampal synaptic dysfunction in a murine model of human immunodeficiency virus type 1 encephalitis. Neuroscience (2003) 0.89
Expression of human immunodeficiency virus type 1 in the nervous system of transgenic mice leads to neurological disease. J Virol (1994) 0.89
Pneumonia associated with HIV infection. Curr Opin Infect Dis (2005) 0.89
Vacuolar myelopathy in transgenic mice expressing human immunodeficiency virus type 1 proteins under the regulation of the myelin basic protein gene promoter. Nat Med (1996) 0.88
Delineating HIV-associated neurocognitive disorders using transgenic models: the neuropathogenic actions of Vpr. J Neuroimmune Pharmacol (2011) 0.88
Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101(+) patients protected mice against chimaeric ecotropic HIV-1 challenge. Eur J Immunol (2009) 0.88
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2007) 2.43
Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. J Virol (2006) 2.24
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood (2006) 2.13
Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol (2007) 2.05
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.01
Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One (2008) 1.99
Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol (2009) 1.85
Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol (2007) 1.84
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol (2007) 1.80
CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol (2012) 1.78
HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab (2006) 1.72
NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond) (2009) 1.72
Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One (2008) 1.65
Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. J Leukoc Biol (2003) 1.62
A functional transsulfuration pathway in the brain links to glutathione homeostasis. J Biol Chem (2006) 1.61
STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood (2007) 1.60
Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol (2010) 1.57
NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond) (2009) 1.55
Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood (2005) 1.54
HIV-1-associated dementia: a basic science and clinical perspective. AIDS Read (2002) 1.54
Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine (Lond) (2011) 1.52
Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. Neurobiol Dis (2007) 1.52
Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res (2006) 1.50
A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron (2009) 1.48
Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol (2005) 1.46
HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J Acquir Immune Defic Syndr (2002) 1.46
Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood (2010) 1.44
Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol (2010) 1.42
Biochemical and biologic characterization of exosomes and microvesicles as facilitators of HIV-1 infection in macrophages. J Immunol (2012) 1.42
Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology (2006) 1.41
HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1beta. Glia (2006) 1.40
A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug Chem (2007) 1.38
Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmune Pharmacol (2006) 1.37
Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J Neurochem (2007) 1.35
Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res (2007) 1.35
Cell-mediated drug delivery. Expert Opin Drug Deliv (2011) 1.33
Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS (2012) 1.32
HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis (2010) 1.32
Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS One (2009) 1.31
Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. Virology (2007) 1.30
Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci (2003) 1.28
Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release (2010) 1.28
Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol (2009) 1.27
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci (2009) 1.27
CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol (2010) 1.27
CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J (2010) 1.25
Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. J Infect Dis (2012) 1.23
Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol (2002) 1.23
Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J Neurosci (2011) 1.22
Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia (2003) 1.22
Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.22
CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One (2009) 1.21
Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine (2013) 1.21
Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal (2009) 1.20
Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob Agents Chemother (2013) 1.17
CSF proteomic fingerprints for HIV-associated cognitive impairment. J Neuroimmunol (2007) 1.16
Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci (2005) 1.16
Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. J Neurochem (2007) 1.15
Nitrated alpha-synuclein and microglial neuroregulatory activities. J Neuroimmune Pharmacol (2008) 1.15
Neuromodulatory activities of CD4+CD25+ regulatory T cells in a murine model of HIV-1-associated neurodegeneration. J Immunol (2009) 1.14
Neurodegenerative disorders and nanoformulated drug development. Nanomedicine (Lond) (2009) 1.14
Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+CD25+ T cells. J Proteome Res (2009) 1.13
Cytoskeletal protein transformation in HIV-1-infected macrophage giant cells. J Immunol (2007) 1.13
Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease. PLoS One (2012) 1.13
Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine (Lond) (2010) 1.12
Macrophage-induced inflammation affects hippocampal plasticity and neuronal development in a murine model of HIV-1 encephalitis. Glia (2005) 1.12
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. Int J Nanomedicine (2011) 1.11
Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS. J Neuroimmune Pharmacol (2010) 1.10
Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis. Am J Pathol (2010) 1.09
Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J Leukoc Biol (2006) 1.08
Impaired spatial cognition and synaptic potentiation in a murine model of human immunodeficiency virus type 1 encephalitis. J Neurosci (2002) 1.08
Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. Int J Nanomedicine (2012) 1.08
Tracking superparamagnetic iron oxide labeled monocytes in brain by high-field magnetic resonance imaging. J Neurosci Res (2003) 1.08
Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis. J Immunol (2007) 1.07
Memantine protects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis. J Neurosci (2004) 1.06
Immune privilege and HIV-1 persistence in the CNS. Immunol Rev (2006) 1.05
HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: new insights into blood-brain barrier dysfunction for HIV-1-associated dementia. J Neuroimmunol (2007) 1.05
UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 1.05
Methamphetamine-associated psychosis. J Neuroimmune Pharmacol (2011) 1.05
Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs. J Vis Exp (2010) 1.03
Neuroregulatory events follow adaptive immune-mediated elimination of HIV-1-infected macrophages: studies in a murine model of viral encephalitis. J Immunol (2004) 1.03
Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J Control Release (2010) 1.03
Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (Lond) (2013) 1.03
Molecular characterization of a putative antiretroviral transcriptional factor, OTK18. J Immunol (2004) 1.02
Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol (2009) 1.02
Human immunodeficiency virus type 1 endocytic trafficking through macrophage bridging conduits facilitates spread of infection. J Neuroimmune Pharmacol (2011) 1.02
CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neuroimmunol (2006) 1.02
Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia. J Neuroimmunol (2003) 1.01